circadian rhythm comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
== History == Vinblastine was first isolated by Robert Noble and Charles Thomas Beer at the University of Western Ontario from the Madagascar periwinkle plant. The structure of Vinblastine and Vincristine are very similar. There are some differences in their pharmacological effects only and there is no cross-resistance. Vinblastine's utility as a chemotherapeutic agent was first suggested by its effect on the body when an extract of the plant was injected in rabbits to study the plant's supposed anti-diabetic effect. (A tea made from the plant was a folk-remedy for diabetes.) The rabbits died from a bacterial infection, due to a decreased number of white blood cells, so it was hypothesized that vinblastine might be effective against cancers of the white blood cells such as lymphoma. It was approved by FDA in 1965.
=== Sericin === Sericin is a group of water-soluble proteins that coat the fibroin filaments and bind them together within the cocoon. In suture manufacture and most biomaterial processing it is removed during a step called degumming, in part because early studies associated it with inflammation and allergic reactions. That association has since been re-examined, and purified sericin is used in its own right—in coatings, gels, cosmetics and pharmaceuticals—for its capacity to retain moisture and its antioxidant activity. Recovering sericin from silk-processing wastewater also makes use of a material that would otherwise be discarded.
In 1955, Harry Winokur worked with brother-in-law William Rosenberg, the founder of Dunkin' Donuts. After Winokur broke his partnership with Rosenberg, he went on to create Mister Donut with his son-in-law, David Slater that same year, with stores in most of North America. The Mister Donut business became so popular that Winokur and Slater decided to go into franchising. As a result, Mister Donut began a rapid expansion that resulted in the opening of 275 stores in the U.S. and Canada. In 1970, Minneapolis-based International Multifoods Corporation, one of the world's largest and most successful food companies, acquired Mister Donut and its franchising concept from Winokur. The first Mister Donut outlet in Japan opened in Minoh, Osaka in 1971. Also in the same year, a Mister Donut training center was constructed in Japan. In 1973, the French cruller became available in Japanese stores. In 1978, brothers Sutthichai and Sutthikiat Chirathiwat, on behalf of Thai Franchise Co., Ltd, opened the first Mister Donut store in Siam Square, Bangkok. The two would come to pioneer the donut market within Thailand. In 2003, Mister Donut in Thailand came under the management of CRG. Donut Thailand (Central Restaurants Group) which continues to manage the company in Thailand. In 1983, Duskin Co., Ltd. of Osaka, Japan, acquired the rights to franchise Mister Donut throughout Japan and Asia.
For example, the International Brain Research Organization was founded in 1961, the International Society for Neurochemistry in 1963, the European Brain and Behaviour Society in 1968, and the Society for Neuroscience in 1969. Recently, the application of neuroscience research results has also given rise to applied disciplines as neuroeconomics, neuroeducation, neuroethics, and neurolaw. Over time, brain research has gone through philosophical, experimental, and theoretical phases, with work on neural implants and brain simulation predicted to be important in the future.
Sources: en.wikipedia.org
Absorption is the journey of a drug travelling from the site of administration to the site of action. The drug travels by some route of administration (oral, topical-dermal, etc.) in a chosen dosage form (e.g., tablets, capsules, or in solution). Absorption by some other routes, such as intravenous therapy, intramuscular injection, enteral nutrition, is even more straightforward and there is less variability in absorption and bioavailability is often near 100%. Intravascular administration does not involve absorption, and there is no loss of drug. The fastest route of absorption is inhalation. Absorption is a primary focus in drug development and medicinal chemistry, since a drug must be absorbed before any medicinal effects can occur. Moreover, the drug's pharmacokinetic profile can be easily and significantly changed by adjusting factors that affect absorption.
In 2004, Maheshwari joined the University of Alabama at Birmingham, Alabama as an assistant professor. He studied innate immunity and the pathogenesis of gut mucosal and systemic inflammation in newborn infants, with a particular focus on a disease called necrotizing enterocolitis (NEC). In this disease, the intestines of a premature or critically ill infant become inflamed and lose viability. His research was supported by the American Gastroenterological Association and the National Institutes of Health. In 2010, he moved to the University of Illinois College of Medicine at Chicago, Illinois as the Head of Neonatology. In 2014, he was recruited to the University of South Florida as the Pamela and Leslie Muma Professor, Head of Neonatology, and Assistant Dean for Medical Education. He administered the academic and the clinical programs at the neonatal intensive care unit at Tampa General Hospital. In his laboratory, he investigated the role of intestinal macrophages and platelets in intestinal inflammation. In 2018, he relocated to the Johns Hopkins University School of Medicine, Baltimore, Maryland as the Josephine S. Sutland Professor of Newborn Medicine, Head of Neonatology, and vice-chairman of the Department of Pediatrics.
Viruses containing positive-strand RNA or double-strand RNA, except retroviruses and Birnaviridae All positive-strand RNA eukaryotic viruses with no DNA stage, such as Coronaviridae All RNA-containing bacteriophages; the two families of RNA-containing bacteriophages are Fiersviridae (positive ssRNA phages) and Cystoviridae (dsRNA phages) dsRNA virus family Reoviridae, Totiviridae, Hypoviridae, Partitiviridae Mononegavirales (negative-strand RNA viruses with non-segmented genomes; InterPro: IPR016269) Negative-strand RNA viruses with segmented genomes (InterPro: IPR007099), such as orthomyxoviruses and bunyaviruses dsRNA virus family Birnaviridae (InterPro: IPR007100) Flaviviruses produce a polyprotein from the ssRNA genome. The polyprotein is cleaved to a number of products, one of which is NS5, an RdRp. It possesses short regions and motifs homologous to other RdRps. RNA replicase found in positive-strand ssRNA viruses are related to each other, forming three large superfamilies. Birnaviral RNA replicase is unique in that it lacks motif C (GDD) in the palm. Mononegaviral RdRp (PDB 5A22) has been automatically classified as similar to (+)−ssRNA RdRps, specifically one from Pestivirus and one from Leviviridae. Bunyaviral RdRp monomer (PDB 5AMQ) resembles the heterotrimeric complex of Orthomyxoviral (Influenza; PDB 4WSB) RdRp.
Sources: en.wikipedia.org
The 2014 Farm Bill legalized the sale of "non-viable hemp material" grown within states participating in the Hemp Pilot Program which defined hemp as cannabis containing less than 0.3% of THC. The 2018 Farm Bill removed the hemp plant and all "derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis," including CBD, from the Controlled Substances Act, making them legal to manufacture in the United States. The FDA retains regulatory authority over hemp-derived CBD, while the DEA is not involved in the regulation of legally-compliant hemp and hemp products. The 2018 Farm Bill requires that research and development of CBD for a therapeutic purpose would have to be conducted under notification and reporting to the FDA. On April 23, 2026, the Department of Justice issued an order to immediately reclassify medical cannabis as a Schedule III controlled substance when dispensed by a state-licensed cannabis dispensary. The DEA is in the process of conducting expedited public hearings to address the broader rescheduling of all cannabis from Schedule I to Schedule III, with the hearings scheduled to begin June 29, 2026.
The Students' Union's primary role is to provide a recognised representative channel between undergraduates and the university and college authorities. In February 2009, the university announced the Students' Union-run RAG Week would "no longer form part of the university calendar". The President of the Students' Union expressed the belief that the decision was unjustified, citing the more than €20,000 raised for charities that year. RAG Week continued unofficially until 2024, when the fundraising event returned with support from the Students' Union.
== Education == Lectka completed his bachelor's in chemistry and graduated from Oberlin College in 1985. He completed his doctoral degree in organic chemistry from Cornell University in 1991. He then completed his postdoctoral studies as an Alexander von Humboldt Postdoctoral Fellow at the University of Heidelberg in Germany and then as a National Institutes of Health Postdoctoral Fellow at Harvard University.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.